Kura Oncology, Inc.

NASDAQ:KURA

8.89 (USD) • At close February 4, 2025
Bedrijfsnaam Kura Oncology, Inc.
Symbool KURA
Munteenheid USD
Prijs 8.89
Beurswaarde 691,319,293
Dividendpercentage 0%
52-weken bereik 6.98 - 24.17
Industrie Biotechnology
Sector Healthcare
CEO Dr. Troy Edward Wilson J.D., Ph.D.
Website https://kuraoncology.com

An error occurred while fetching data.

Over Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the

Vergelijkbare Aandelen

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.463 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

2.51 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

5.12 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.438 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

3.17 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

50.21 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

12.49 USD

Phibro Animal Health Corporation logo

Phibro Animal Health Corporation

PAHC

22.02 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

14.41 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)